Stockscreener 앱 받기
7.18
0.69%
-0.05
시장 영업 전:
7.09
-0.09
-1.25%
Immunitybio Inc 주식(IBRX)의 최신 뉴스
ImmunityBio stock rises after FDA compliance response - Investing.com
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook - Yahoo Finance
ImmunityBio Inc stock (US45258J1025): HC Wainwright reiteration follows Nasdaq pullback - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Investors to Inquire about Securities Investigation - ACCESS Newswire
IBRX Reiterates by HC Wainwright -- Price Target Maintained at $15 - GuruFocus
ImmunityBio (IBIO) Showcases Promising Clinical Data for ANKTIVA at ASCO 2026 - GuruFocus
ImmunityBio presents ANKTIVA data at ASCO meeting By Investing.com - Investing.com Nigeria
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 - The AI Journal
ImmunityBio presents ANKTIVA data at ASCO meeting - Investing.com
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio: Anktiva Explained and What Comes Next - The Globe and Mail
IBRX and the BCG Shortage: Deals That Could Expand Demand - Yahoo Finance
IBRX Stock Outlook After Q1 Results and a New FDA Review - Yahoo Finance
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200 - Yahoo Finance
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX) - Yahoo Finance
Is ImmunityBio Inc. (IBRX) One of the Best Momentum Stocks to Buy According to Analysts? - Insider Monkey
ImmunityBio Company Profile & Introduction - Moomoo
IBRX stock rises overnight: Investors eye FDA workshop on Anktiva after exclusive Japan BCG deal - MSN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX - GlobeNewswire Inc.
IBRX Stock Jumps As ANKTIVA Bladder Cancer Story Strengthens - StocksToTrade
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - Caledonian Record
IBRX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts ImmunityBio, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
IBRX Stock Climbs As ANKTIVA Franchise Momentum Builds - timothysykes.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. LawsuitIBRX - Morningstar
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Voice of Alexandria
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman - Barchart.com
Virtus Investment Advisers, LLC's ImmunityBio Inc(IBRX) Holding History - GuruFocus
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. ... - Caledonian Record
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS - marketscreener.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ImmunityBio, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
IBRX stock jumps overnight after major FDA review win for Anktiva in bladder cancer - MSN
IBRX 2-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - marketscreener.com
IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS - Morningstar
symbol__ Stock Quote Price and Forecast - CNN
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. ... - Caledonian Record
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc.IBRX - Business Wire
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar - GlobeNewswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential - GlobeNewswire
IBRX says ANKTIVA delivers up to $314K cost advantage over J&J's TAR-200 — everything to know about ImmunityBio’s findings - MSN
ImmunityBio presents UK bladder cancer patient survey data By Investing.com - Investing.com South Africa
Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer - Stocktwits
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with N - pharmiweb.com
IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s Findings - Yahoo Finance
1.59%
0.77%
자본화:
|
볼륨(24시간):